**17.2 IL-13 inhibitor**

RPC4046 (a humanized monoclonal antibody against IL13) was found to improve dysphagia, and reduce histologic and endoscopic features compared with placebo in a phase II trial. The medication was also found to be safe and well tolerated [51].
